Oblique will be presenting at the RAS-Targeted Drug Discovery Europe Summit in February
Oblique Therapeutics is on EU-Startups top 10 list -“10 European biotech startups to look out for in 2019 and beyond”
We are proud to have been recognised by StartUp City Magazine as one of the most promising European Biotech startups in 2019!
We welcome our new owners
New collaboration with Pharma
Oblique Therapeutics at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
Oblique Therapeutics presents tumor growth inhibition and Treg-lowering data for OT-1096 in humanized mouse TNBC model at oncology congress ESMO